MedTrace Logo

Paclitaxel/Carboplatin With or Without Cetuximab in CUP

NCT00894569 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2009-05-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether an addition of cetuximab to carboplatin/paclitaxel can improve efficacy in comparison to carboplatin/paclitaxel in patients with carcinoma of unknown-primary.

Conditions

  • Neoplasms, Unknown Primary
  • Carcinoma

Interventions

DRUG

paclitaxel/carboplatin

6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.

DRUG

cetuximab

cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Alwin Kraemer, Prof. Dr. · University of Heidelberg, Medic. Dep. V

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-07-31
Completion
2011-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00894569 on ClinicalTrials.gov